


PRODUCT INFORMATION



Fumonisin B₁ Item No. 62580

CAS Registry No.: 116355-83-0
Formal Name: (2R,2'R)-1,2,3-propanetricarboxylic acid, 1,1'-[(1S,2R)-1-[(2S,4R,9R,11S,12S)-12-amino-4,9,11-trihydroxy-2-methyltridecyl]-2-[(1R)-1-methylpentyl]-1,2-ethanediyl] ester

Synonym: FB₁
MF: C₃₄H₅₉NO₁₅
FW: 721.8
Purity: ≥95%
Supplied as: A crystalline solid
Storage: -20°C
Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly



Laboratory Procedures

Fumonisin B₁ is supplied as a crystalline solid. A stock solution may be made by dissolving the fumonisin B₁ in an organic solvent purged with an inert gas. Fumonisin B₁ is soluble in solvents such as methanol and acetonitrile. The solubility of fumonisin B₁ in these solvents is approximately 10 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant since organic solvents may have physiological effects at low concentrations. If an organic solvent-free solution of fumonisin B₁ is needed, it can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of fumonisin B₁ in PBS (pH 7.2) is approximately 18.5 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Fumonisin B₁ is a mycotoxin produced by *F. moniliforme*, a prevalent fungus of corn and other grains. Outbreaks of food poisoning in livestock and humans following the consumption of *Fusarium* infested corn are caused by fumonisins.¹ It functions as an inhibitor of ceramide synthase (sphingosine N-acyltransferase).² Fumonisin B₁ attenuates the response of P388D1 cells to PAF and LPS by inhibiting ceramide formation.³ It also blocks the apoptotic response of HaCaT cells to the antiproliferative drug hexadecylphosphocholine, again through inhibition of ceramide production.⁴ Incubation of Swiss 3T3 cells with fumonisin B₁ results in both an altered cell morphology due to disruption of axonal growth and a decrease in cell proliferation.⁵

References

1. Gelderblom, W.C.A., Jaskiewicz, K., Marasas, W.F.O., *et al.* *Appl. Environ. Microbiol.* **54**, 1806-1811 (1988).
2. Wang, E., Norred, W.P., Bacon, C.W., *et al.* *J. Biol. Chem.* **266**, 14486-14490 (1991).
3. Balsinde, J., Balboa, M.A., and Dennis, E.A. *J. Biol. Chem.* **272**, 20373-20377 (1997).
4. Wieder, T., Orfanos, C.E., and Geilen, C.C. *J. Biol. Chem.* **273**, 11025-11031 (1998).
5. Meivar-Levy, I., Sbanay, H., Bershadsky, A.D., *et al.* *J. Biol. Chem.* **272**, 1558-1564 (1997).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/30/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM